Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA Biosciences (Nasdaq: IDYA) has nominated IDE892 as a development candidate, representing their 7th development candidate overall. IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor designed for treating MTAP-deletion solid tumors.
The compound demonstrates favorable drug-like properties and has shown exceptional selective antiproliferative activity in MTAP-deleted tumor cell models. When combined with MAT2A inhibitor IDE397, it achieved durable complete responses in preclinical models.
The company is currently conducting IND-enabling studies and targets an IND filing with the FDA in mid-2025, subject to successful completion of ongoing preclinical studies.
IDEAYA Biosciences (NASDAQ: IDYA) has announced that its Compensation Committee granted non-qualified stock options to a newly hired employee on December 2, 2024. The grant includes options to purchase 170,000 shares of common stock at an exercise price of $27.45 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the company's 2023 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) has announced its participation in two upcoming investor events in December 2024. The company will participate in Citi's 2024 Global Healthcare Conference on December 3rd at 8:00 AM ET, featuring a fireside chat with CEO Yujiro S. Hata. Additionally, IDEAYA will attend the 7th Annual Evercore HealthCONx Conference on December 4th at 1:20 PM ET. Live audio webcasts will be available on IDEAYA's website investor section, with replays accessible for 30 days after the events.
IDEAYA Biosciences announced that its Compensation Committee granted non-qualified stock options to purchase 33,300 shares of common stock to a newly hired employee on November 27, 2024. The options, granted under the 2023 Employment Inducement Incentive Award Plan, have an exercise price of $26.99 per share, matching the closing price on Nasdaq. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years, subject to continued employment.
IDEAYA Biosciences (IDYA) has appointed Stu Dorman as Chief Commercial Officer. Dorman brings over 20 years of oncology commercialization experience from Gilead Sciences and Bristol Myers Squibb. At Gilead, as VP of U.S. Oncology, he built a commercial organization achieving billion-dollar global sales. During his 14-year tenure at BMS, he led commercial strategy for key products including Opdivo. The appointment comes as IDEAYA advances its darovasertib trials in first-line HLA-A2(-) MUM and neoadjuvant UM, along with IDE397 development in MTAP-deletion cancers.
IDEAYA Biosciences (NASDAQ: IDYA) announced its upcoming participation in two key events: the Jefferies London Healthcare Conference on November 19th, 2024, featuring a fireside chat with CEO Yujiro S. Hata, and an Investor R&D Day scheduled for December 16th, 2024. The R&D Day will showcase IDEAYA's potential first-in-class preclinical and clinical pipeline, featuring presentations from management, Key Opinion Leaders, and pharmaceutical partners. Both events will be accessible via webcast through IDEAYA's investor relations website, with recordings available for 30 days after the live events.
IDEAYA Biosciences announced the nomination of IDE034 as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC). The company exercised its option for an exclusive worldwide license from Biocytogen Pharmaceuticals, targeting an IND-filing in 2025 for first-in-human trials. IDE034 shows promise as both a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161. B7H3/PTK7 co-expression in lung, colorectal, and head and neck cancers has been reported at 30%, 46%, and 27%, respectively. The licensing agreement includes upfront and option exercise fees, along with additional milestone payments, totaling $406.5 million.
IDEAYA Biosciences reported significant progress in Q3 2024, including completion of a $302.4 million follow-on financing. The company highlighted positive developments across multiple clinical programs, notably darovasertib enrollment exceeding 150 patients and IDE397 showing promising results in MTAP-deletion cancers with confirmed ORR of 40% in UC and 38% in SqNSCLC. The company has $1.2 billion in cash, expected to fund operations into 2028. Key developments include FDA IND clearance for IDE275, successful Type C meeting for darovasertib's Phase 3 trial, and ongoing progress in multiple clinical trials. The company plans to nominate three new development candidates by year-end 2024.
IDEAYA Biosciences issued a correction to their Q3 2024 financial results, specifically regarding enrollment in the darovasertib + crizotinib trial for HLA-A2(-) MUM patients. Key highlights include: enrollment exceeding 150 patients ahead of schedule, successful FDA Type C meeting for darovasertib in neoadjuvant UM, and positive Phase 2 results showing ~49% patients with >30% ocular tumor shrinkage. The company reported IDE397 showed confirmed response rates of 40% in UC and 38% in SqNSCLC. With $1.2 billion in cash as of September 2024, operations are funded into 2028. The company completed a $302.4 million follow-on financing and received IND clearance for IDE275, earning a $7.0 million milestone from GSK.
IDEAYA Biosciences (NASDAQ: IDYA) announced that its Compensation Committee granted non-qualified stock options to two newly hired employees on October 31, 2024. The grants, made under the company's 2023 Employment Inducement Incentive Award Plan, total 62,800 shares with an exercise price of $28.15 per share, matching the closing price on Nasdaq that day. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years, contingent on continued employment.